FR2666227A1 - Composition therapeutique notamment pour le traitement des affections de la cavite buccale. - Google Patents
Composition therapeutique notamment pour le traitement des affections de la cavite buccale. Download PDFInfo
- Publication number
- FR2666227A1 FR2666227A1 FR9011041A FR9011041A FR2666227A1 FR 2666227 A1 FR2666227 A1 FR 2666227A1 FR 9011041 A FR9011041 A FR 9011041A FR 9011041 A FR9011041 A FR 9011041A FR 2666227 A1 FR2666227 A1 FR 2666227A1
- Authority
- FR
- France
- Prior art keywords
- sep
- menthol
- cyclodextrin
- therapeutic composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 22
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 77
- 229940041616 menthol Drugs 0.000 claims abstract description 77
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 58
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 230000002195 synergetic effect Effects 0.000 claims abstract description 9
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 7
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 83
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 26
- 102000016943 Muramidase Human genes 0.000 claims description 13
- 108010014251 Muramidase Proteins 0.000 claims description 13
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 13
- 229960000274 lysozyme Drugs 0.000 claims description 13
- 235000010335 lysozyme Nutrition 0.000 claims description 13
- 239000004325 lysozyme Substances 0.000 claims description 13
- 229940011671 vitamin b6 Drugs 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000008160 pyridoxine Nutrition 0.000 claims description 10
- 239000011677 pyridoxine Substances 0.000 claims description 10
- 229960004873 levomenthol Drugs 0.000 claims description 9
- 210000000214 mouth Anatomy 0.000 claims description 9
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 4
- 239000011885 synergistic combination Substances 0.000 claims description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940073475 lysozyme hydrochloride Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 2
- 229960004853 betadex Drugs 0.000 abstract 2
- 229930003270 Vitamin B Natural products 0.000 abstract 1
- 235000010603 pastilles Nutrition 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 29
- 229940097362 cyclodextrins Drugs 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000001013 cariogenic effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000212342 Sium Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000001755 (-)-menthol group Chemical group 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 0 CC(C)C1*(C)CCCC1 Chemical compound CC(C)C1*(C)CCCC1 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002249 decongestive effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- -1 methyl 1-isopropyl Chemical group 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9011041A FR2666227A1 (fr) | 1990-09-05 | 1990-09-05 | Composition therapeutique notamment pour le traitement des affections de la cavite buccale. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9011041A FR2666227A1 (fr) | 1990-09-05 | 1990-09-05 | Composition therapeutique notamment pour le traitement des affections de la cavite buccale. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2666227A1 true FR2666227A1 (fr) | 1992-03-06 |
| FR2666227B1 FR2666227B1 (enrdf_load_stackoverflow) | 1994-12-02 |
Family
ID=9400106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9011041A Granted FR2666227A1 (fr) | 1990-09-05 | 1990-09-05 | Composition therapeutique notamment pour le traitement des affections de la cavite buccale. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2666227A1 (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003709A1 (fr) * | 1993-07-30 | 1995-02-09 | Firmenich S.A. | Procede d'aromatisation |
| EP0803243A3 (en) * | 1996-04-24 | 1997-11-12 | Pfizer Inc. | Cyclodextrins and phenolic compounds in dental products |
| WO2006020190A1 (en) * | 2004-07-16 | 2006-02-23 | Richard Plymale | Dentifrice composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5366M (enrdf_load_stackoverflow) * | 1964-12-05 | 1967-10-16 | ||
| GB2007090A (en) * | 1977-11-07 | 1979-05-16 | Toko Yakuhin Kogyo Kk | Composition for topical preparations and process for producing the same |
| JPS61218513A (ja) * | 1985-03-23 | 1986-09-29 | Sunstar Inc | 香味の変化する歯磨組成物 |
| JPS61260017A (ja) * | 1985-05-15 | 1986-11-18 | Rooto Seiyaku Kk | う蝕予防効果を有する口腔用組成物 |
| WO1988008304A1 (en) * | 1987-04-23 | 1988-11-03 | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. | Pharmaceutical composition |
| JPS63277612A (ja) * | 1987-05-11 | 1988-11-15 | Lion Corp | 口腔用組成物 |
-
1990
- 1990-09-05 FR FR9011041A patent/FR2666227A1/fr active Granted
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5366M (enrdf_load_stackoverflow) * | 1964-12-05 | 1967-10-16 | ||
| GB2007090A (en) * | 1977-11-07 | 1979-05-16 | Toko Yakuhin Kogyo Kk | Composition for topical preparations and process for producing the same |
| JPS61218513A (ja) * | 1985-03-23 | 1986-09-29 | Sunstar Inc | 香味の変化する歯磨組成物 |
| JPS61260017A (ja) * | 1985-05-15 | 1986-11-18 | Rooto Seiyaku Kk | う蝕予防効果を有する口腔用組成物 |
| WO1988008304A1 (en) * | 1987-04-23 | 1988-11-03 | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. | Pharmaceutical composition |
| JPS63277612A (ja) * | 1987-05-11 | 1988-11-15 | Lion Corp | 口腔用組成物 |
Non-Patent Citations (3)
| Title |
|---|
| Base de données WPIL de DERWENT; numéro d'acces 86-344276 & JP-A-61 260017 (ROHTO PHARMACEUTICAL KK) 18 novembre 1985 * |
| PATENT ABSTRACTS OF JAPAN vol. 011, no. 060 (C-405) 24 février 1987, & JP-A-61 218513 (SUNSTAR INC) 29 septembre 1986 * |
| PATENT ABSTRACTS OF JAPAN vol. 013, no. 101 (C-574) 09 mars 1989, & JP-A-63 277612 (LION CORP) 15 novembre 1988 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003709A1 (fr) * | 1993-07-30 | 1995-02-09 | Firmenich S.A. | Procede d'aromatisation |
| EP0803243A3 (en) * | 1996-04-24 | 1997-11-12 | Pfizer Inc. | Cyclodextrins and phenolic compounds in dental products |
| US6942848B2 (en) | 1996-04-24 | 2005-09-13 | Warner-Lambert Company Llc | Cyclodextrins in dental products |
| WO2006020190A1 (en) * | 2004-07-16 | 2006-02-23 | Richard Plymale | Dentifrice composition |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2666227B1 (enrdf_load_stackoverflow) | 1994-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2768479B1 (en) | Excipients for nicotine-containing therapeutic compositions | |
| CA2683436C (en) | Melatonin tablet and methods of preparation and use | |
| EP2364144B1 (en) | Dosage form for insertion into the mouth | |
| EP0399902B1 (fr) | Nouvelle forme pharmaceutique poreuse et sa préparation | |
| JP5213446B2 (ja) | ジクロフェナクを含む医薬組成物 | |
| CZ156598A3 (cs) | Použití flurbiprofenu k přípravě léčiva k léčení bolesti v krku | |
| AU2015289150B2 (en) | Orodispersible film | |
| JP7723417B2 (ja) | 低中毒性抗コリン作動性エステルのための方法および組成物 | |
| RU2755087C1 (ru) | Композитный состав парацетамола для перорального применения | |
| EP0494297B1 (fr) | Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine | |
| FR2604360A1 (fr) | Medicament a liberation controlee pour fournir des ions fluorure | |
| FR2666227A1 (fr) | Composition therapeutique notamment pour le traitement des affections de la cavite buccale. | |
| EP2879663B1 (fr) | Pastilles a cinetiques multiples de liberation de principes actifs | |
| EP3027064B1 (fr) | Composition pharmaceutique, diététique ou alimentaire liquide ou semi-liquide dépourvue d'amertume contenant un sel d'arginine | |
| WO2005084703A1 (ja) | 徐放性の口腔用組成物 | |
| JP5455203B2 (ja) | フィルム製剤およびその製造方法 | |
| FR2560047A1 (fr) | Compositions de bromocriptine | |
| EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
| EP3551164B1 (fr) | Médicament oral comprenant un laxatif osmotique incorporé dans une matrice à base de matières grasses végétales | |
| AU717600B2 (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
| JP2022102546A (ja) | オリーブエキス、及びヒドロキシチロソール含有コーティング錠剤 | |
| JPH0463545A (ja) | チューインガム | |
| FR2624737A1 (fr) | Extrait de feuilles de cassis obtenu par extraction hydroalcoolique, procede de preparation d'un tel extrait; et composition therapeutique, notamment a activite antalgique et anti-inflammatoire comprenant un tel extrait | |
| CN111787906A (zh) | 含有无可可碱的可可的口服剂型 | |
| FR2638971A1 (fr) | Comprime a delitement et/ou dissolution instantane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CD | Change of name or company name | ||
| ST | Notification of lapse |
Effective date: 20080531 |